<SEC-DOCUMENT>0001140361-22-042770.txt : 20221122
<SEC-HEADER>0001140361-22-042770.hdr.sgml : 20221122
<ACCEPTANCE-DATETIME>20221122160602
ACCESSION NUMBER:		0001140361-22-042770
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20221122
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Termination of a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221122
DATE AS OF CHANGE:		20221122

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Eterna Therapeutics Inc.
		CENTRAL INDEX KEY:			0000748592
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				311103425
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11460
		FILM NUMBER:		221410335

	BUSINESS ADDRESS:	
		STREET 1:		10355 SCIENCE CENTER DRIVE
		STREET 2:		SUITE 150
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		(212) 582-1199

	MAIL ADDRESS:	
		STREET 1:		10355 SCIENCE CENTER DRIVE
		STREET 2:		SUITE 150
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Brooklyn ImmunoTherapeutics, Inc.
		DATE OF NAME CHANGE:	20210325

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN BUZZTIME INC
		DATE OF NAME CHANGE:	20051230

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN COMMUNICATIONS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>brhc10044587_8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:erna="http://eternatx.com/20221122" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 22.10.2.5096
         Copyright 1995 - 2022 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_03e4128df7834f93a97b1f502aef391e" contextRef="c20221122to20221122" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_d21cadcbe58e46f381861ad4aa5c3cf4" contextRef="c20221122to20221122">0000748592</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="erna-20221122.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20221122to20221122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-22</xbrli:startDate><xbrli:endDate>2022-11-22</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" />
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a id="z_Hlk104309906"></a><a id="z_Hlk104320152"></a><span style="font-size: 14pt;">UNITED STATES</span></div>

  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>

  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_217d0d6047b045fda35c1646e44159ce" contextRef="c20221122to20221122">8-K</ix:nonNumeric></div>

  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>

  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_c339b38506a8478bb01a6843f4dcb7af" contextRef="c20221122to20221122" format="ixt:date-monthname-day-year-en">November 22, 2022</ix:nonNumeric></div>

  <div><br />
  </div>

  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_a9bb8c2a7b834399be9657d6b12f38ae" contextRef="c20221122to20221122">Eterna Therapeutics Inc.</ix:nonNumeric><br />
  </div>

  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">(Exact Name of Registrant as Specified in its Charter)</div>

  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

  <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 32.61%; vertical-align: bottom;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_d3af52b74e6048b29c87d480866ab43b" contextRef="c20221122to20221122" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
          </div>
        </td>

    <td style="width: 33.68%; vertical-align: bottom;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_b7a3616c6d5948afa9e7dceb23d59db1" contextRef="c20221122to20221122">001-11460</ix:nonNumeric><br />
          </div>
        </td>

    <td style="width: 33%; vertical-align: bottom;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_838369af58854121be31bcdc242b5a5f" contextRef="c20221122to20221122">31-1103425</ix:nonNumeric><br />
          </div>
        </td>

  </tr>

  <tr>

    <td style="width: 32.61%; vertical-align: top;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">(State or Other Jurisdiction of Incorporation)</div>
        </td>

    <td style="width: 33.68%; vertical-align: top;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">(Commission File Number)</div>
        </td>

    <td style="width: 33%; vertical-align: top;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">(IRS Employer Identification No.)</div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49.01%; vertical-align: bottom;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_649cd7249c474ba1996032e6aafc417c" contextRef="c20221122to20221122">10355 Science Center Drive</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_db3366b7fe38434db31ecd977cc9d1eb" contextRef="c20221122to20221122">Suite 150</ix:nonNumeric></div>
        </td>

    <td style="width: 2%; vertical-align: bottom;">
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
        </td>

    <td style="width: 49%; vertical-align: bottom;">
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
        </td>

  </tr>

  <tr>

    <td style="width: 49.01%; vertical-align: bottom;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_03dabcf9e5f646f5aeba7bf25781ffc6" contextRef="c20221122to20221122">San Diego</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_65011ccbe94445cc91864d3c96f28f8f" contextRef="c20221122to20221122" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></div>
        </td>

    <td style="width: 2%; vertical-align: bottom;">
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
        </td>

    <td style="width: 49%; vertical-align: bottom;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_a97486e4a9004b9d9bacb1cb9b1d4dba" contextRef="c20221122to20221122">92121</ix:nonNumeric><br />
          </div>
        </td>

  </tr>

  <tr>

    <td style="width: 49.01%; vertical-align: bottom;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">(Address of Principal Executive Offices)</div>
        </td>

    <td style="width: 2%; vertical-align: bottom;">
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
        </td>

    <td style="width: 49%; vertical-align: bottom;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">(Zip Code)</div>
        </td>

  </tr>


</table>
  <div><br />
  </div>

  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Registrant&#8217;s telephone number, including area code:&#160;<span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_d37dff11b12e46a98a230cd189c843d1" contextRef="c20221122to20221122">212</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_b60e5d417348465b95ca78f6a7716c5d" contextRef="c20221122to20221122">582-1199</ix:nonNumeric></span></div>

  <div><br />
  </div>

  <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>

  <div><br />
  </div>

  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; text-align: left; font-family: 'Segoe UI Symbol',sans-serif; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_6ef625b4cbff4a1e85b1c8e2d893e091" contextRef="c20221122to20221122" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left;">
          <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; text-align: left; font-family: 'Segoe UI Symbol',sans-serif; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_cb89d9517e764ba88d24b897f82c5818" contextRef="c20221122to20221122" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left;">
          <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; text-align: left; font-family: 'Segoe UI Symbol',sans-serif; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_7706a301393a4f10b8253c6bda6f0557" contextRef="c20221122to20221122" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left;">
          <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; text-align: left; font-family: 'Segoe UI Symbol',sans-serif; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_68cdc5dbd5134a2c89ec37f689d20ea9" contextRef="c20221122to20221122" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
        </td>

    <td style="width: auto; vertical-align: top; text-align: left;">
          <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
        </td>

  </tr>


</table>
  <div><br />
  </div>

  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

  <div><br />
  </div>

  <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 41.3%; vertical-align: bottom; border-bottom: #000000 2px solid;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Title of each class</div>
        </td>

    <td style="width: 0.96%; vertical-align: middle;">
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
        </td>

    <td style="width: 18.76%; vertical-align: bottom; border-bottom: #000000 2px solid;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Trading symbol</div>
        </td>

    <td style="width: 2%; vertical-align: middle;">
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
        </td>

    <td style="width: 36.98%; vertical-align: top; border-bottom: #000000 2px solid;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Name of each exchange on which registered</div>
        </td>

  </tr>

  <tr>

    <td style="width: 41.3%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_d13d434f94124e2d8b7181cc098edd56" contextRef="c20221122to20221122">Common Stock, par value $0.005 per share</ix:nonNumeric><br />
          </div>
        </td>

    <td style="width: 0.96%; vertical-align: middle;">
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
        </td>

    <td style="width: 18.76%; vertical-align: top;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_f56b83e8a9d54968b294b55290642b9d" contextRef="c20221122to20221122">ERNA</ix:nonNumeric><br />
          </div>
        </td>

    <td style="width: 2%; vertical-align: middle;">
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
        </td>

    <td style="width: 36.98%; vertical-align: top;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_6789f5a257014ce5a34025632cc25691" contextRef="c20221122to20221122" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric><br />
          </div>
        </td>

  </tr>


</table>
  <div><br />
  </div>

  <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange
    Act of 1934:</div>

  <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_1feef8f272394e04b911a34fbea15e24" contextRef="c20221122to20221122" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></div>

  <div><br />
  </div>

  <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
    financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<span style="font-size: 10pt; font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</span></div>

  <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Segoe UI Symbol', sans-serif;"> <br />
    </span></div>

  <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
    <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" />
<div><span style="font-size: 10pt; font-family: 'Segoe UI Symbol', sans-serif;"> </span></div>
</div>

  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

  </div>

  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 54pt; vertical-align: top; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 1.01</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Entry into a Material Definitive Agreement.</div>
        </td>

  </tr>


</table>
  <div>&#160;</div>

  <div>
    <div style="text-align: justify; text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">On November 22, 2022 (the &#8220;<span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="text-decoration: underline;">Amendment Effective Date</span></span>&#8221;),
      Eterna Therapeutics Inc., a Delaware corporation (the &#8220;<span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="text-decoration: underline;">Company</span></span>&#8221;), entered into a First Amendment (the &#8220;<span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="text-decoration: underline;">Amendment</span></span>&#8221;)



      to the Exclusive License Agreement, dated as of April 26, 2021 (the &#8220;<span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="text-decoration: underline;">Original License Agreement</span></span>,&#8221; and as amended by the Amendment, the &#8220;<span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="text-decoration: underline;">Amended Factor License Agreement</span></span>&#8221;), by and among Brooklyn Immunotherapeutics LLC, a wholly owned subsidiary of the Company (&#8220;<span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="text-decoration: underline;">Brooklyn
          LLC</span></span>&#8221;), Novellus Therapeutics Limited, a wholly owned subsidiary of the Company (&#8220;<span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="text-decoration: underline;">Novellus</span></span>&#8221;), and Factor Bioscience Limited (&#8220;<span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="text-decoration: underline;">Factor</span></span>&#8221;).&#160; Pursuant to the Amendment, among other things, Factor has granted to Brooklyn LLC an exclusive, sublicensable license under certain patents owned by Factor (the &#8220;<span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="text-decoration: underline;">Factor Patents</span></span>&#8221;) for the purpose of identifying and pursuing certain opportunities to grant to third parties sublicenses to the Factor Patents. The Amendment also (i) terminated the
      Novellus-Factor License Agreement (as defined below), (ii) confirmed Factor&#8217;s grant to Brooklyn LLC of the rights and licenses Novellus previously granted to Brooklyn LLC under the Novellus-Factor License Agreement on the same terms and conditions as
      granted by Novellus to Brooklyn LLC under such agreement, (iii) confirmed that sublicense granted by Novellus in accordance with the Novellus-Factor License Agreement to NoveCite, Inc. (the &#8220;<span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="text-decoration: underline;">NoveCite Agreement</span></span>&#8221;), in which the Company has a 25% ownership interest (&#8220;<span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="text-decoration: underline;">NoveCite</span></span>&#8221;), survives termination of the Novellus-Factor License Agreement;
      and (iv) removed Novellus from the Amended Factor License Agreement and the NoveCite Agreement and replaced Novellus with Factor as the direct licensor to Brooklyn LLC and NoveCite under such agreements, respectively.</div>

    <div>&#160;</div>

    <div style="text-align: justify; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">On </span>November 1, 2020, Novellus and Factor entered into<span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> the </span>Third Amended and Restated Exclusive License Agreement, dated as of November 1, 2020 (the &#8220;<span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"><span style="text-decoration: underline;">Novellus-Factor License Agreement</span></span>&#8221;), by and between Novellus and Factor, pursuant to which Factor granted to Novellus an exclusive license under <span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">certain



        patents owned by Factor</span>&#160;<span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">for the development of certain stem cell-based cellular therapies for treating diseases and conditions in humans and animals (the &#8220;<span style="text-decoration: underline;">Novellus-Factor


          Licensed Technology</span>&#8221;), and under which Novellus in turn, under the Original License Agreement, granted a sublicense to Brooklyn LLC to use the Novellus-Factor Licensed Technology to develop, use and commercialize certain stem cell-based
        therapy products for use in the treatment of cancer in humans. On November 1, 2022, one of the delineated milestone deadlines for certain regulatory filings required under the Novellus-Factor License Agreement expired, which permitted Factor to
        terminate the license granted to Novellus thereunder, subject to Factor&#8217;s agreement under the Original License Agreement that upon such a termination of the Novellus-Factor License Agreement, the rights and licenses granted to Brooklyn LLC by
        Novellus under the Original License Agreement would survive such termination of the Novellus-Factor License Agreement, and Factor&#8217;s agreement to grant to Brooklyn LLC such rights and licenses on the same terms and conditions as granted by Novellus
        to Brooklyn LLC under the Original License Agreement, which agreement was effected by the Amendment.&#160; Similarly, under the Amendment, the NoveCite Agreement has been continued as a direct license between Factor and NoveCite.</span></div>

    <div>&#160;</div>

    <div style="text-align: justify; text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the Amendment, the Company has agreed to guaranty all payments and other obligations of Brooklyn LLC owed to Factor
      under the Amended Factor License Agreement.&#160; The exclusive license granted to Brooklyn LLC under the Amendment is subject to sublicenses or other rights previously granted by Factor to third parties as of November 1, 2022.&#160; The term of the license
      granted under the Amendment is five years from the Amendment Effective Date and is extendable for an additional two and a half years if Brooklyn LLC receives at least $100 million from sublicenses granted by it with respect to the sublicensing
      opportunities contemplated by the Amendment.&#160; Brooklyn LLC may not develop or commercialize products by itself under the license granted in the Amendment, but it maintains its right to develop and commercialize the products specified under the
      Original License Agreement.&#160; Additionally, Brooklyn LLC may not pursue any sublicensing opportunity under the license granted in the Amendment for which it does not have the resources sufficient to pursue, including the financial resources necessary
      to defend any claim, action or proceeding that may arise as a result of or in connection with such pursuit.</div>

    <div>&#160;</div>

    <div style="text-align: justify; text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Under the Amendment, Brooklyn LLC has agreed to pay to Factor 20% of the sublicense fees received by Brooklyn LLC under the
      sublicenses granted with respect to the sublicensing opportunities that are identified during the first five-year term of the license granted under the Amendment and 30% of any sublicense fees received by Brooklyn LLC under the sublicenses granted
      with respect to the sublicensing opportunities that are identified during the potential two and a half year extension period of the term of the license granted under the Amendment.&#160; Brooklyn LLC also agreed to pay the expenses incurred by Factor in
      preparing, filing, prosecuting and maintaining the Factor Patents and has agreed to bear all costs and expenses associated with enforcing and defending the Factor Patents in any action or proceeding arising from pursuit of sublicensing opportunities
      under the license granted in the Amendment.</div>

    <div>&#160;</div>

  </div>

  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

  </div>

  <div>
    <div style="text-align: justify; text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Factor may terminate the license granted under the Amendment upon 30 days&#8217; written notice to Brooklyn LLC, provided that the license
      granted under the Amendment may not be terminated (i) during the first 60 days following the Amendment Effective Date and (ii) for an additional 60 days so long as Brooklyn LLC and Factor are negotiating in good faith to amend and restate the Amended
      Factor License Agreement. In the event of the termination of the license granted under the Amendment, Brooklyn LLC has the right to continue pursuing sublicenses with respect to opportunities that Brooklyn LLC identified prior to the effective date
      of termination of the license granted under the Amendment for up to one year following such termination and collect any compensation received under any such sublicenses entered into with respect to such identified opportunities, subject to payment to
      Factor of the fees to which it is entitled under the Amendment, and provided that such opportunities are expressly made subject to the provisions of the Amendment.&#160; Additionally, subject to certain conditions, any other sublicenses granted by
      Brooklyn LLC in accordance with the Amendment shall survive the termination of the Amended Factor License Agreement and shall be considered direct licenses from Factor to the sublicensees under such sublicenses.</div>

    <div>&#160;</div>

    <div style="text-align: justify; text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Additionally, during the term of the license granted under the Amendment, Brooklyn LLC may identify two opportunities as &#8220;Surviving
      Opportunities&#8221; for which Brooklyn LLC may pursue sublicense for up to four years following termination of the license granted under the Amendment and collect any compensation received under any such sublicenses, subject to payment to Factor of the
      fees to which it is entitled under the Amendment.&#160; Upon the termination of the license granted under the Amendment and in the event the parties are unable to resolve any dispute regarding the Surviving Opportunities, or at Brooklyn LLC&#8217;s election,
      Factor has agreed to assume the Surviving Opportunities and pay to Brooklyn LLC 80% of all amounts received by Factor pursuant to sublicenses entered into with respect to such Surviving Opportunities within the four-year period following such
      termination.</div>

    <div>&#160;</div>

    <div style="text-align: justify; text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Dr. Matthew Angel, the Company&#8217;s interim President and Chief Executive Officer, is the co-founder, President, CEO, and a director of
      Factor Bioscience Inc., which is the parent of Factor.</div>

    <div>&#160;</div>

    <div style="text-align: justify; text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The foregoing description of the Amendment is only a summary and is qualified in its entirety by reference to the full text of the
      Amendment, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference in this Item 1.01.</div>

    <div>&#160;</div>

  </div>

  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 54pt; vertical-align: top; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 1.02</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Termination of a Material Definitive Agreement.</div>
        </td>

  </tr>


</table>
  <div>&#160;</div>

  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 24.5pt;">The information contained in Item 1.01 of this Current Report on Form 8-K with respect to the <span style="font-size: 10pt; font-family: 'Times New Roman';">Novellus-Factor License Agreement </span>is hereby incorporated by reference in response to this Item 1.02</div>

  <div><br />
  </div>

  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 54pt; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 7.01</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Regulation FD Disclosure.</div>
        </td>

  </tr>


</table>
  <div>&#160;</div>

  <div>
    <div style="text-align: justify; text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">In connection with the execution of the Amendment, the Company has currently identified US Patent Numbers 10,662,410, 10,829,738,
      and 10,982,229, included in the Factor Patents as having potential licensing partners. The Company currently intends to explore sublicensing arrangements with these potential partners; however, the Company can provide no assurance that it will be
      able to enter into any such sublicensing arrangements with such partners, or others, on favorable terms or at all.</div>

    <div>&#160;</div>

  </div>

  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 54pt; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 9.01</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Financial Statements and Exhibits.</div>
        </td>

  </tr>


</table>
  <div>&#160;</div>

  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">(d) Exhibits.</div>

  <div>&#160;</div>

  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 12%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
          <div style="font-weight: bold;">
            <div style="text-align: center;">Exhibit<br />
              Number</div>
          </div>
        </td>

    <td colspan="1" style="width: 2%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;">&#160;</td>

    <td style="width: 86%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
          <div style="font-weight: bold;">
            <div style="text-align: center;"><br />
              Description</div>
          </div>
        </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"><a href="brhc10044587_ex10-1.htm">10.1</a>*</div>
        </td>

    <td colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 86%; vertical-align: top;">
          <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">First Amendment to Exclusive License Agreement, dated November 22, 2022, by and among Eterna Therapeutics Inc., Brooklyn Immunotherapeutics LLC,
            Novellus Therapeutics Limited and Factor Bioscience Limited.</div>
        </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">104</div>
        </td>

    <td colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 86%; vertical-align: top;">
          <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</div>
        </td>

  </tr>


</table>
  <div style="text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">*</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">Pursuant to Item 601(a)(5) of Regulation
      S-K, schedules and similar attachments to this exhibit have been omitted because they do not contain information material to an investment or voting decision and such information is not otherwise disclosed in such exhibit. The Company will
      supplementally provide a copy of any omitted schedule or similar attachment to the U.S. Securities and Exchange Commission or its staff upon request.</span></div>

  <div style="text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> <br />
    </span></div>

  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

  </div>

  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SIGNATURE</div>

  <div><br />
  </div>

  <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto
    duly authorized.</div>

  <div><br />
  </div>

  <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49.72%; vertical-align: top;">&#160;</td>

    <td colspan="3" style="width: 50.28%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-variant: small-caps;">Eterna Therapeutics Inc.</div>
        </td>

  </tr>

  <tr>

    <td style="width: 49.72%; vertical-align: top;">&#160;</td>

    <td colspan="3" style="width: 50.28%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
        </td>

  </tr>

  <tr>

    <td style="width: 49.72%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Dated: November 22<span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">, 2022</span></div>
        </td>

    <td style="width: 3.82%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">By:</div>
        </td>

    <td style="width: 45.44%; vertical-align: top; border-bottom: #000000 2px solid;">
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">/s/ Andrew Jackson</div>
        </td>

    <td style="width: 1.01%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 49.72%; vertical-align: top;">&#160;</td>

    <td style="width: 3.82%; vertical-align: top;">&#160;</td>

    <td style="width: 45.44%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Chief Financial Officer</div>
        </td>

    <td style="width: 1.01%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
        </td>

  </tr>


</table>
  <div><br />
  </div>

  <div><br />
  </div>

  <div>
    <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>brhc10044587_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 22.10.2.5096
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <!--PROfilePageNumberReset%Num%1%%%--> <font style="font-size: 10pt;"> </font>
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div style="text-align: right;"><font style="font-weight: bold; font-size: 10pt;">Exhibit 10.1</font><font style="font-size: 10pt;"><br>
    </font></div>
  <div style="text-align: right;"><font style="font-weight: bold;"> </font><font style="font-size: 10pt;"><br>
    </font>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">This FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Amendment</font>&#8221;),
      entered into as of November 22, 2022 (the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Amendment</font>&#160;<font style="font-family: 'Times New Roman'; font-weight: bold;">Effective Date</font>&#8221;), is made and entered into by and
      among Eterna Therapeutics Inc. (&#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Eterna</font>&#8221;), Brooklyn Immunotherapeutics LLC (&#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Licensee</font>&#8221;), Novellus
      Therapeutics Limited (&#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Novellus</font>&#8221;) and Factor Bioscience Limited (&#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Factor</font>&#8221;). Each of Eterna, Licensee,
      Novellus and Factor is referred to herein as a <font style="font-family: 'Times New Roman'; font-weight: bold;">Party</font> and together, the <font style="font-family: 'Times New Roman'; font-weight: bold;">Parties</font>.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">WHEREAS, Factor and Novellus entered into that certain Third Amended and Restated Exclusive License Agreement, dated as of November 1, 2020 (the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Two-Party Agreement</font>&#8221;), pursuant to which Factor granted to Novellus an exclusive license under the Licensed Technology, the Auxiliary Technologies, and the Auxiliary Technology
      Patents to Exploit Licensed Products in the Territory in the Field during the Term (as those terms are defined in the Two-Party Agreement);</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">WHEREAS, Factor, Novellus, and Licensee entered into that certain Exclusive License Agreement, dated as of April 26, 2021 (as amended by that certain
      letter agreement by and among the Parties, dated as of November 15, 2022, the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Three-Party Agreement</font>&#8221;), pursuant to which Factor and Novellus granted to Licensee an exclusive
      license under the Licensed Technology, the Auxiliary Technologies, and the Auxiliary Technology Patents to Exploit Licensed Products in the Territory in the Field during the Term (as those terms are defined in the Three-Party Agreement);</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">WHEREAS, the Two-Party Agreement provides Factor the right to terminate the Two-Party Agreement if Novellus has not submitted an IND for any Licensed
      Product in the Field on or before the date that is two (2) years after the Third Amendment Effective Date (as those terms are defined in the Two-Party Agreement) and Novellus did not submit an IND for any Licensed Product in the Field on or before
      such date;</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">WHEREAS, Factor wishes to grant to Licensee, and Licensee wishes to accept, an exclusive, sublicensable license under the Factor Patents (as defined
      below) for the purpose of identifying and pursuing opportunities to grant sublicenses under the Factor Patents in the Territory to third parties as described herein; and</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">WHEREAS, the terms of the Three-Party Agreement may be modified if such modification is made in writing and signed by a duly authorized officer of
      each Party pursuant to Section 11.4 thereof.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">NOW, THEREFORE, in consideration of the mutual covenants and obligations set forth out in this Amendment and other good and valuable consideration,
      the sufficiency of which are acknowledged, the Parties hereby agree as follows:</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> Eterna will be
          responsible as a guarantor for all payments and other obligations of Licensee owed to Factor under the Three-Party Agreement, including, but not limited to, all payments set forth therein, and any obligations that matured prior to the Amendment
          Effective Date and payment thereof shall remain an ongoing obligation of Eterna until such amounts are paid in full.</font></font></div>
    <br>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">1</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"></div>
    </div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">2.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The Two-Party
          Agreement is hereby terminated in accordance with Section 7.2.3 of the Two-Party Agreement. In accordance with Section 11.16.5 of the Three-Party Agreement, Factor agrees that the rights and licenses granted to Licensee by Novellus thereunder
          shall survive such termination of the Two-Party Agreement and Factor hereby grants to Licensee such rights and licenses on the same terms and conditions as granted by Novellus to Licensee in the Three-Party Agreement. In accordance with Section
          7.7 of the Two-Party Agreement, Novellus hereby requests that that certain License Agreement dated as of October 6, 2020 by and between Novellus and Novecite, Inc. (as amended, the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Novecite
            Agreement</font>&#8221;), as a sublicense under the Two-Party Agreement, survive such termination and that the license granted by Novellus to Novecite, Inc. under the Novecite Agreement be considered a direct license from Factor to Novecite, Inc. and
          Factor hereby agrees to said request. Novellus is eliminated from the Three-Party Agreement and the Novecite Agreement and is replaced by Factor as the direct Licensor to Licensee.&#160; Licensee hereby agrees that Factor shall be entitled to enforce
          all applicable provisions of the Three-Party Agreement directly against Licensee with respect to the licenses granted to Licensee thereunder, and all applicable provisions of the Novecite Agreement with respect to the licenses granted to
          Novecite, Inc. thereunder, and Factor shall not assume, and shall not be responsible to Novecite for, any representations, warranties or obligations of Novellus to Novecite under the Novecite Agreement, other than to permit Novecite to exercise
          any rights to the Licensed Technology, Auxiliary Technologies, and the Auxiliary Technology Patents previously sublicensed to Novecite by Novellus pursuant to the Novecite Agreement.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">3.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The title of
          Section 2 of the Three-Party Agreement shall be amended and restated as follows:</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8220;Product Development Licenses&#8221;</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">4.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The following
          Section 2A shall be inserted in the Three-Party Agreement immediately following Section 2 and before Section 3:</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Section 2A</font></div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><u>Identified Opportunity Licenses</u></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2A.1. <font style="font-family: 'Times New Roman'; font-style: italic;"><u>License Grant</u></font>.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div>
      <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In addition to the licenses granted to Licensee under Section 2 and subject to Section 2A.3, Factor hereby grants to Licensee
        an exclusive (even as to the Factor), non-transferrable (except in accordance with Section 11.2) license, with the right to grant sublicenses pursuant to Section 2A.2, under the Factor Patents in the Territory for any and all uses during the
        Opportunity Term.</div>
      <div style="font-size: 10pt;">&#160;</div>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">2</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
    </div>
    <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2A.2. <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Sublicensing</u></font>.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On an Identified Opportunity-by-Identified Opportunity basis, Licensee may sublicense the rights granted to it under Section 2A.1
      to third party sublicensees (each such third party sublicensee, an &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Opportunity Sublicensee</font>&#8221;, such sublicense, an &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Opportunity Sublicense</font>&#8221;) during the Identification Period, so long as: (a) the Opportunity Sublicense is royalty-bearing and in writing; (b) the terms of the Opportunity Sublicense include customary terms for such types of
      sublicenses, including, without limitation, terms that are substantially consistent (subject to conforming revisions to refer to the rights licensed to and products to be Exploited by the applicable Opportunity Sublicensee) with the terms and
      conditions of Sections 3, 5.3.7, 5.4 (if payments are based on ongoing product sales), 5.5, 5.6, 6.3, 6.4, 6.5, 7.6, and 7.10 of&#160; this Agreement, and, if the applicable Opportunity Sublicense is an exclusive license granted for the purpose of
      Exploitation of Opportunity Products, include the obligation of the Opportunity Sublicensee to use Commercially Reasonable Efforts to Exploit one or more Opportunity Products; (c) the Opportunity Sublicense was negotiated by Licensee in good faith,
      for a proper purpose and on reasonable arm&#8217;s-length commercial terms; (d) the Opportunity Sublicense names Factor as a third-party beneficiary thereof; (e) the Opportunity Sublicensee has, or has the ability to acquire, adequate resources (including
      scientific, technical and financial) to perform its obligations under such Opportunity Sublicense, as reasonably determined by Licensee at the time of entry into the Opportunity Sublicense; and (f) a complete, confidential copy of the Opportunity
      Sublicense agreement and any amendments thereto are provided to Factor within thirty (30) days of the execution of said Opportunity Sublicense agreement or any such amendments thereto. In each case, Licensee will be responsible for enforcing the
      performance of the Opportunity Sublicensees under the Opportunity Sublicenses, including, without limitation, making any payments provided for hereunder. Subject to Section 8.6, Licensee will provide Factor with a complete, confidential copy of each
      such Opportunity Sublicense agreement executed by Licensee and any amendments thereto, and will promptly notify Factor of the termination of any such Opportunity Sublicense.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2A.3. <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Retained Rights</u></font>.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2A.3.1 The license granted to Licensee under Section 2A.1 is subject to Factor&#8217;s right to make and use, and permit academic,
      government, and not-for-profit institutions or agencies to make and use the inventions disclosed in the Factor Patents for non-commercial research, academic, educational, and all other non-commercial purposes and for the commercial or non-commercial
      provision by Factor of research services to third parties. Subject to the terms of this Agreement, any commercial provision of research services by Factor to a third party will be subject to a written agreement between Factor and such third party
      that grants such third party a license under the Factor Patents to use such research services only for non-commercial purposes.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2A.3.2. The license granted to Licensee under Section 2A.1 is subject to any licenses or other rights already granted by Factor
      to third parties as of November 1, 2022, and as set forth on Appendix B hereto (the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Prior Agreements</font>&#8221;).</div>
    &#160; <br>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">3</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"></div>
    </div>
    <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2A.4. <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Consideration</u></font>.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In consideration for the rights granted by Factor to Licensee under Section 2A.1, Licensee shall, within thirty (30) days of
      receiving any Opportunity Sublicense Fees, pay to Factor (i) twenty percent (20%) of such Opportunity Sublicense Fees received in connection with any Identified Opportunities Identified during the Initial Identification Period and (ii) thirty percent
      (30%) of any Opportunity Sublicense Fees received in connection with any Identified Opportunities Identified during the Extended Identification Period. For clarity, the Opportunity Sublicense Fee due under this Section 2A.4 shall only apply to
      Opportunity Sublicenses and not to any sublicenses granted pursuant to Sections 2.1 or 2.2. Sections 5.3, 5.4, 5.5 and 5.6 of this Agreement shall apply <font style="font-family: 'Times New Roman'; font-style: italic;">mutatis mutandis</font> to any
      Opportunity Sublicense Fees to be paid to Factor.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2A.5. <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Representations, Warranties, and Covenants of Factor</u></font>.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2A.5.1 Factor hereby represents and warrants to Licensee that, as of the Amendment Effective Date and continuing for the entire
      Opportunity Term, subject to Section 2A.3.2 of this Agreement, it is the sole and exclusive owner or licensee of the Factor Patents, and it has the right, power and authority to grant the rights set forth in Section 2A.1 of this Agreement;</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2A.5.2&#160; Factor hereby represents and warrants to Licensee that as of the Amendment Effective Date, there are no judgments or
      settlements against or owed by Factor or its Affiliates or, to its knowledge, pending or threatened claims or litigation, in either case relating to the Factor Patents;</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2A.5.3 Factor hereby covenants to Licensee, during the Opportunity Term, that Factor shall, at Licensee&#8217;s reasonable request and
      at Licensee&#8217;s sole cost and expense, join any proceedings reasonably necessary to Pursue Opportunity Sublicenses;</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2A.5.4 Factor hereby covenants to Licensee, during the Opportunity Term, that Factor shall, at Licensee&#8217;s request from time to
      time, update Appendix C; and</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2A.5.5 Factor hereby covenants to Licensee, during the Opportunity Term, that it shall inform Licensee of any Opportunities it
      becomes aware of, provided that doing so does not violate any obligation of confidentiality owed by Factor to a third party, or shall refer such Opportunities to Licensee to pursue.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2A.6. <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Representations, Warranties, and Covenants of
          Licensee</u></font>.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2A.6.1 Licensee hereby represents and warrants to Factor that, as of the Amendment Effective Date, the execution and performance
      of Licensee&#8217;s obligations under this Agreement do not conflict with, cause a default under, or violate any existing contractual obligation that may be owed by Licensee to any third party, including, without limitation, any Affiliate of Licensee;</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2A.6.2 Licensee hereby represents and warrants to Factor that, as of the Amendment Effective Date, there is no action or suit
      pending against Licensee or any of its Affiliates that questions the validity of this Agreement or the right of Licensee to enter into this Agreement or consummate the transactions contemplated hereby;</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2A.6.3 Licensee hereby covenants to Factor, during the Opportunity Term, that, subject to Section 2.1, Licensee will not develop
      or commercialize any Opportunity Product by itself or through any Affiliate of Licensee;</div>
    &#160; <br>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">4</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"></div>
    </div>
    <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2A.6.4 Licensee hereby covenants to Factor, during the Opportunity Term, that, Licensee will not Pursue any Opportunity for which
      it does not have resources sufficient to Pursue such Opportunity, including, without limitation, financial resources necessary to defend any claim, action or proceeding that may arise as a result of or in connection with such Pursuit;</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2A.6.5 Licensee hereby covenants to Factor, during the Opportunity Term, that, in the event of any dispute or disagreement
      between Factor and Licensee as to the Pursuit of any Opportunity (or the performance of any obligations hereunder with respect thereto, including, without limitation any alleged breach of the representations, warranties, and covenants set forth in
      Section 2A.6 of this Agreement) that could reasonably result in irreparable harm to the validity or enforceability of one or more Factor Patents, Licensee shall immediately cease Pursuing any Opportunities that are the subject of such dispute or
      disagreement, and shall not resume Pursuing any such Opportunities unless and until such dispute or disagreement is resolved in accordance with the provisions set forth in Section 10 of the Agreement; and</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2A.6.6 Licensee hereby covenants to Factor that, prior to granting an Opportunity Sublicense, Licensee and Factor shall cooperate
      reasonably to determine whether the granting of such Opportunity Sublicense would cause Factor to be in material breach of any of the Prior Agreements.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Sections 6.3, 6.4, 7.6, and 11.13 of this Agreement shall apply <font style="font-family: 'Times New Roman'; font-style: italic;">mutatis mutandis</font> to the Factor Patents.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2A.9. <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Protection of Intellectual Property Rights</u></font>.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2A.9.1 Notwithstanding anything in this Agreement to the contrary, during the Opportunity Term, Factor, in consultation with
      Licensee, will be responsible for, using counsel of its choosing and at Licensee&#8217;s sole expense, preparing, filing, prosecuting and maintaining the Factor Patents.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2A.9.2 Subject at all times to the rights granted by Factor to its third-party licensees under the Prior Agreements, Licensee
      shall have the sole right to enforce the Factor Patents and shall defend the Factor Patents in any action or proceeding, including, but not limited to, any declaratory judgment action or administrative proceeding arising from Pursuit of Opportunity
      Licenses, which alleges the invalidity, unenforceability or non-infringement of any of the rights associated with the Factor Patents. All costs and expenses associated with enforcing and defending the Factor Patents in any such action or proceeding
      will be borne by Licensee and Licensee shall be entitled to any recovery or compensation resulting from enforcement or defense of the Factor Patents, but shall reimburse Factor for reasonable out of pocket expenses incurred by Factor in providing
      cooperation and/or participating in such proceedings and shall pay to Factor the applicable consideration with respect to Opportunity Sublicense Fees received by Licensee with respect thereto, in accordance with Section 2A.4 above. Factor will
      cooperate and provide reasonable assistance in any action or proceeding described in this Section 2A.9.2.</div>
    &#160; <br>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">5</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"></div>
    </div>
    <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2A.10. <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Term and Termination</u></font>.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2A.10.1 <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Term</u></font>. This Section 2A is effective as of
      the Amendment Effective Date and, unless earlier terminated pursuant to the provisions of Section 2A.10.2 of this Agreement, will expire, in its entirety, upon the expiration of the Identification Period (the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Opportunity Term</font>&#8221;).</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2A.10.2 <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Termination</u></font>. Factor may, at its option,
      terminate this Section 2A. upon thirty (30) days&#8217; advance written notice to Licensee, provided that this termination right shall not be exercisable during the first sixty (60) days after the Amendment Effective Date, and provided further that Factor
      shall not exercise this termination right for an additional sixty (60) days if Licensee is negotiating in good faith with Factor with respect to the terms for an amended and restated exclusive license agreement amending and restating the Agreement
      containing mutually acceptable additional terms with respect to Pursuit of Opportunities.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2A.10.3 <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Effects of</u></font><font style="font-family: 'Times New Roman';"><u>&#160;</u></font><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Termination</u></font>. Subject to Section 2A.10.4, upon termination of this Section 2A, Licensee&#8217;s right to the Factor Patents which have been
      granted under this Section 2A and all use thereof will terminate. Expiration or termination of this Section 2A will not release either Party from any obligation that matured prior to the effective date of such expiration or termination.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2A.10.4 <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Effects on Identified Opportunities and Opportunity
          Sublicenses</u></font>. Notwithstanding anything to the contrary, Licensee shall have the right to continue Pursuing Opportunity Sublicenses with respect to Opportunities that Licensee has Identified prior to the effective date of termination of
      this Section 2A for up to one (1) year from the effective date of termination of this Section 2A, and collect any compensation received under any such Opportunity Sublicenses entered into with respect to such Identified Opportunities, subject to
      payment to Factor of the compensation applicable with respect thereto in accordance with Section 2A.4 above, and provided that such Identified Opportunities are expressly made subject to the provisions of this Agreement, including the covenants of
      Licensee set forth in Section 2A.6.4 and 2A.6.5, which shall survive any termination of this Section 2A with respect to such Identified Opportunities. Additionally, any other Opportunity Sublicenses granted by Licensee in accordance with this
      Agreement shall survive the termination of this Agreement or this Section 2A. The surviving Opportunity Sublicenses shall be considered direct licenses from Factor to such surviving Opportunity Sublicensee; provided that such Opportunity Sublicensee
      agrees in writing that (i) Factor is entitled to enforce all relevant provisions directly against such Opportunity Sublicensee, and (ii) Factor shall not assume, and shall not be responsible to such Opportunity Sublicensee for, any representations,
      warranties or obligations of Licensee to such Opportunity Sublicensee, other than to permit such Opportunity Sublicensee to exercise any rights to the Factor Patents sublicensed to such sublicensee by Licensee. During the Opportunity Term, Licensee
      may, at Licensee&#8217;s sole discretion, identify two Opportunities, whether or not such Opportunities are Identified Opportunities, as &#8220;Surviving Opportunities&#8221;. Notwithstanding anything to the contrary, Licensee shall have the right to continue Pursuing
      Opportunity Sublicenses with respect to the Surviving Opportunities for up to four (4) years from the effective date of termination of this Section 2A, and collect any compensation received under any such Opportunity Sublicenses entered into with
      respect to such Surviving Opportunities, subject to payment to Factor of the compensation applicable with respect thereto in accordance with Section 2A.4 above. Licensee&#8217;s right to Pursue the Surviving Opportunities is expressly made subject to the
      provisions of this Agreement, including the covenants of Licensee set forth in Section 2A.6.4 and 2A.6.5, which shall survive any termination of this Section 2A with respect to such Surviving Opportunities. Upon the termination of this Section 2A and
      in the event the Parties are unable to resolve any dispute regarding the Surviving Opportunities, or at Licensee&#8217;s election, Factor shall assume the Surviving Opportunities and pay to Licensee 80% of all amounts received by Factor pursuant to
      Opportunity Sublicenses entered into with respect to such Surviving Opportunities, provided that such Opportunity Sublicenses are entered into within four (4) years from the effective date of such termination of this Section 2A.</div>
    <div style="font-size: 10pt;">&#160; <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">6</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"></div>
    </div>
    <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2A.10.5 <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Survival</u></font>. Notwithstanding anything to
      the contrary, this Section 2A shall survive the expiration or termination of the Agreement unless terminated in accordance with the terms of this Section 2A.10.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2A.11 <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Definitions</u></font>. Capitalized terms used but
      not defined herein shall have the meanings given to such terms as set forth in Appendix A hereto or elsewhere in the Agreement.&#8221;</div>
    <div style="font-size: 10pt;">&#160; <br>
    </div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">5.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">New Appendices
          A, B, and C shall be attached to the Three-Party Agreement as set forth in Appendices A, B, and C of this Amendment.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">6.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Upon execution,
          this Amendment shall be made a part of the Three-Party Agreement and shall be incorporated by reference therein.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">7.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">This Amendment
          may be executed by original or facsimile signature in any number of counterparts, each of which need not contain the signature of more than one Party but all such counterparts taken together will constitute one and the same agreement.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">8.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The persons
          signing on behalf of each Party hereby warrant and represent that they have authority to execute this Amendment on behalf of the Party for whom they have signed.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">9.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">All provisions
          of the Three-Party Agreement not expressly modified by this Amendment shall remain in full force and effect. In the event of any conflict between the terms of the Three-Party Agreement and this Amendment, the terms of this Amendment shall govern
          and control.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">10.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The substantive
          law governing this Amendment (which shall be applied in any arbitration) shall be, with respect to disputes involving general contract or trade secret matters, the internal laws of the Commonwealth of Massachusetts, and with respect to matters
          involving patents, the United States Patent Act, as to copyright matters, the United States Copyright Act, and as to trademark matters, the United States Trademark Act, each as amended from time to time. Any award rendered by the Arbitrator shall
          be final, conclusive and binding upon the Parties to this Amendment, and judgment thereon may be entered and enforced in any state or federal court of competent jurisdiction. Notwithstanding anything to the contrary, in the event of any conflict
          between the terms of Section 10 of this Amendment and the Three-Party Agreement, the terms of the Three-Party Agreement shall govern and control.</font></font></div>
    <div style="font-size: 10pt;">&#160; <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">7</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"></div>
    </div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">11.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">If any
          provisions of this Amendment are or will come into conflict with the laws or regulations of any jurisdiction or any governmental entity having jurisdiction over the Parties or this Amendment, those provisions will be deemed automatically deleted,
          if such deletion is allowed by relevant<font style="font-family: 'Times New Roman';"> law, </font>and the remaining terms and conditions of this Amendment will remain in full force and effect. If such a deletion is not so allowed or if such a
          deletion leaves terms thereby made clearly illogical or inappropriate in effect, the Parties agree to substitute new terms as similar in effect to the present terms of this Amendment as may be allowed under Applicable Law. Notwithstanding
          anything to the contrary, in the event of any conflict between the terms of Section 11 of this Amendment and the Three-Party Agreement, the terms of the Three-Party Agreement shall govern and control.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">12.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">All capitalized
          terms used, but not otherwise defined herein, shall have the meanings ascribed to them in Appendix A hereto or the Three-Party Agreement.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">[<font style="font-family: 'Times New Roman'; font-style: italic;">Signature page follows</font>]</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">8</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">IN WITNESS WHEREOF</font><font style="font-size: 10pt;">, the
        Parties hereto have duly executed this First Amendment to Exclusive License Agreement as of the Amendment Effective Date.</font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z38856eaf0b0b47babe425a607b9bcf64">

        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
          </td>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold;">FACTOR BIOSCIENCE LIMITED</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
          </td>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
          </td>
          <td style="width: 3%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman';">By:</div>
          </td>
          <td style="width: 47%; vertical-align: top; border-bottom: 2px solid black; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-style: italic;">/s/ Christopher Rohde</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
          </td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Name:</div>
          </td>
          <td style="width: 45%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Christopher Rohde</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
          </td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Title:</div>
          </td>
          <td style="width: 45%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Director</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="zf3c34cc4fb274c138d85910a2e31d5fd">

        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
          </td>
          <td style="vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold;">ETERNA THERAPEUTICS INC.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
          </td>
          <td style="vertical-align: top; font-size: 10pt;"><br>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
          </td>
          <td style="width: 3%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman';">By:</div>
          </td>
          <td style="width: 47%; vertical-align: top; border-bottom: 2px solid black; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-style: italic;">/s/ Andrew Jackson</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
          </td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Name:</div>
          </td>
          <td style="width: 45%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Andrew Jackson</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
          </td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Title:</div>
          </td>
          <td style="width: 45%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Chief Financial Officer</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="zd8bc87a06bab421fad203ead1749b702">

        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
          </td>
          <td style="vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold;">BROOKLYN IMMUNOTHERAPEUTICS LLC</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
          </td>
          <td style="vertical-align: top; font-size: 10pt;">&#160;</td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
          </td>
          <td style="width: 3%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman';">By:</div>
          </td>
          <td style="width: 47%; vertical-align: top; border-bottom: 2px solid black; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-style: italic;">/s/ Andrew Jackson</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
          </td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Name:</div>
          </td>
          <td style="width: 45%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Andrew Jackson</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
          </td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Title:</div>
          </td>
          <td style="width: 45%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Chief Financial Officer</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z538a13fc69a0488b9478a43d6e27e2b9">

        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
          </td>
          <td style="vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold;">NOVELLUS THERAPEUTICS LIMITED</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
          </td>
          <td style="vertical-align: top; font-size: 10pt;">&#160;</td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
          </td>
          <td style="width: 3%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman';">By:</div>
          </td>
          <td style="width: 47%; vertical-align: top; border-bottom: 2px solid black; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-style: italic;">/s/ Andrew Jackson</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
          </td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Name:</div>
          </td>
          <td style="width: 45%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Andrew Jackson</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
          </td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Title:</div>
          </td>
          <td style="width: 45%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Director and Secretary</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;&#160; <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageFooter" style="width: 100%;">
        <div style="text-align: center;">[<font style="font-family: 'Times New Roman'; font-style: italic;">Signature Page to First Amendment to Exclusive License Agreement</font>]</div>
      </div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"><u>Appendix A</u></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Definitions</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Extended Identification Period</u></font>&#8221; means the period commencing at the end of the Initial
      Identification Period and continuing for two and a half (2.5) years thereafter.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Factor Patents</u></font>&#8221; means, during the term of the Agreement, all Patents owned or Controlled
      by Factor on the Amendment Effective Date and during the term of the Agreement, including as of the Amendment Effective Date, (a) the patents and patent applications set forth on Appendix C, and (b) any reissue, divisional, continuation,
      reexamination, renewal, extension, supplementary protection certificate, or foreign counterpart of each of the patents and patent applications set forth on Appendix C that includes at least one claim that is directed to subject matter disclosed in
      the patents and patent applications described in clause (a) above, and claims priority to such patents and patent applications.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Identification Period</u></font>&#8221; means the Initial Identification Period and the Extended
      Identification Period, if the Success Milestone has been met during the Initial Identification Period, provided that if an Identified Opportunity has been Identified by Licensee prior to the end of the Identification Period, the Identification Period
      shall be automatically extended for an additional one (1) year period, but only with respect to such Identified Opportunity.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Identify</u></font>&#8221; means with respect to an Opportunity and a third party, the execution of a
      term sheet between Licensee and such third party for the Opportunity.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Identified Opportunity</u></font>&#8221; means an Opportunity Identified by Licensee.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Initial Identification Period</u></font>&#8221; means the period commencing on the Amendment Effective
      Date and continuing for five (5) years thereafter.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Opportunity</u></font>&#8221; means with respect to any third party, the opportunity by Licensee to
      sublicense any Factor Patent to such third party.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Opportunity Product</u></font>&#8221; means any product Covered by the Factor Patents.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Opportunity Sublicense</u></font>&#8221; has the meaning set forth in Section 2A.2.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Opportunity Sublicensee</u></font>&#8221; has the meaning set forth in Section 2A.2.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Opportunity Sublicense Fee</u></font>&#8221; means any consideration in any form received by Licensee or
      its Affiliates pursuant to an Opportunity Sublicense or as consideration for or in connection with a sublicense of, or other right, license, option, privilege, or immunity with respect to, any Opportunity Product or any of the rights to the Factor
      Patents granted to Licensee hereunder, including without limitation settlement amounts, license fees, upfront payments, milestone payments, and royalties payable on sales of Opportunity Products.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Opportunity Term</u></font>&#8221; has the meaning set forth in Section 2A.10.1.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Patents</u></font>&#8221; means any patents and provisional and non-provisional patent applications,
      together with all priority applications, additions, divisions, continuations, continuations-in-part, substitutions, and reissues claiming priority thereto, as well as any reexaminations, extensions, registrations, patent term extensions, supplemental
      protection certificates, renewals and the like with respect to any of the foregoing and all foreign counterparts thereof.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Pursue</u></font>&#8221; means with respect to an Opportunity and a third party, the process until
      signing of a definitive agreement between Licensee and such third party for the Opportunity.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Success Milestone</u></font>&#8221; means actual receipt by Licensee of at least $100 million from the
      Opportunity Sublicenses, including but not limited to upfront fees, milestone payments, royalties and other amounts.</div>
    <div style="font-size: 10pt;">&#160; <br>
    </div>
    <div style="font-size: 10pt;"> <br>
    </div>
    <div style="font-size: 10pt;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
  </div>
  <font style="font-size: 10pt;"> </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>erna-20221122.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 22.10.2.5096 Broadridge-->
<xs:schema targetNamespace="http://eternatx.com/20221122" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:erna="http://eternatx.com/20221122" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="erna-20221122_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="erna-20221122_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://eternatx.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>erna-20221122_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 22.10.2.5096 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications_lbl" xml:lang="en-US" id="dei_WrittenCommunications_lbl">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:title="label: WrittenCommunications to dei_WrittenCommunications_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial_lbl" xml:lang="en-US" id="dei_SolicitingMaterial_lbl">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementTenderOffer_lbl">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer_lbl">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine2_lbl">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine3_lbl">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry_lbl" xml:lang="en-US" id="dei_EntityAddressCountry_lbl">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" id="dei_NoTradingSymbolFlag_lbl">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>erna-20221122_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 22.10.2.5096 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://eternatx.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="erna-20221122.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140041311802432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 22, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 22,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-11460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Eterna Therapeutics Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000748592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">31-1103425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10355 Science Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">582-1199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.005 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ERNA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>brhc10044587_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="erna-20221122.xsd" xlink:type="simple"/>
    <context id="c20221122to20221122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <startDate>2022-11-22</startDate>
            <endDate>2022-11-22</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20221122to20221122"
      id="Fact_03e4128df7834f93a97b1f502aef391e">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20221122to20221122"
      id="Fact_d21cadcbe58e46f381861ad4aa5c3cf4">0000748592</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="c20221122to20221122"
      id="Fact_217d0d6047b045fda35c1646e44159ce">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20221122to20221122"
      id="Fact_c339b38506a8478bb01a6843f4dcb7af">2022-11-22</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20221122to20221122"
      id="Fact_a9bb8c2a7b834399be9657d6b12f38ae">Eterna Therapeutics Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20221122to20221122"
      id="Fact_d3af52b74e6048b29c87d480866ab43b">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20221122to20221122"
      id="Fact_b7a3616c6d5948afa9e7dceb23d59db1">001-11460</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20221122to20221122"
      id="Fact_838369af58854121be31bcdc242b5a5f">31-1103425</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20221122to20221122"
      id="Fact_649cd7249c474ba1996032e6aafc417c">10355 Science Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="c20221122to20221122"
      id="Fact_db3366b7fe38434db31ecd977cc9d1eb">Suite 150</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="c20221122to20221122"
      id="Fact_03dabcf9e5f646f5aeba7bf25781ffc6">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20221122to20221122"
      id="Fact_65011ccbe94445cc91864d3c96f28f8f">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20221122to20221122"
      id="Fact_a97486e4a9004b9d9bacb1cb9b1d4dba">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20221122to20221122"
      id="Fact_d37dff11b12e46a98a230cd189c843d1">212</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20221122to20221122"
      id="Fact_b60e5d417348465b95ca78f6a7716c5d">582-1199</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20221122to20221122"
      id="Fact_6ef625b4cbff4a1e85b1c8e2d893e091">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20221122to20221122"
      id="Fact_cb89d9517e764ba88d24b897f82c5818">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20221122to20221122"
      id="Fact_7706a301393a4f10b8253c6bda6f0557">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20221122to20221122"
      id="Fact_68cdc5dbd5134a2c89ec37f689d20ea9">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20221122to20221122"
      id="Fact_d13d434f94124e2d8b7181cc098edd56">Common Stock, par value $0.005 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20221122to20221122"
      id="Fact_f56b83e8a9d54968b294b55290642b9d">ERNA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20221122to20221122"
      id="Fact_6789f5a257014ce5a34025632cc25691">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20221122to20221122"
      id="Fact_1feef8f272394e04b911a34fbea15e24">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M7>EYIK=WDWM)J'7N0;#W\!J-'<V/'[?\ 5!+ P04    " # @'95)!Z;HJT
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M2P$"% ,4    " # @'95!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( ," =E5$Y*IU[@   "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M ," =E697)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ P(!V521QC(QF!   0Q$  !@
M     ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M ," =E6?H!OPL0(  .(,   -              "  :D,  !X;"]S='EL97,N
M>&UL4$L! A0#%     @ P(!V59>*NQS     $P(   L              ( !
MA0\  %]R96QS+RYR96QS4$L! A0#%     @ P(!V51PX9>H_ 0  / (   \
M             ( !;A   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( ,"
M=E4D'INBK0   /@!   :              "  =H1  !X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( ," =E5ED'F2&0$  ,\#   3
M          "  ;\2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D
*/@(   D4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="brhc10044587_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="brhc10044587_8k.htm">brhc10044587_8k.htm</File>
    <File>brhc10044587_ex10-1.htm</File>
    <File>erna-20221122.xsd</File>
    <File>erna-20221122_lab.xml</File>
    <File>erna-20221122_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "brhc10044587_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "brhc10044587_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "erna-20221122_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "erna-20221122_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "erna-20221122.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 29,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "erna",
   "nsuri": "http://eternatx.com/20221122",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10044587_8k.htm",
      "contextRef": "c20221122to20221122",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000100 - Document - Document and Entity Information",
     "role": "http://eternatx.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10044587_8k.htm",
      "contextRef": "c20221122to20221122",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001140361-22-042770-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-22-042770-xbrl.zip
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MES!;".0Y/+L#; DB+P6U(@>A!;F<\Q #/D;B%&XIR.D4XC:>O_C*>EG2 /+
MD"<)1 DA.,?7!\:!^#ZGC%7?98@F/CXT4;N-63G%+\8?ZY /8K:$S@L84WW:
M(J$[4*EGE:]*-/*3)G^M,FA6 :N>/;9&K@E/O^$Y" Q-JL?(R+2>6/[[.M'?
M9@T"B<YRL%^BUG19@MTXE16<TXSI"L7&-'*L8&)S\-Y>8/FA-V&V9WBN2P-[
M'.QFH+ ,AFE$R>=Y=H,PH65ZRQ-Z2_/UO++6L)IR2KZ:[R7;ACOCD>M]3]QY
M%R<<KH&UUE@!_F#LFF[H,L>W/1I1GT]8R -K##^PP-PJ6S8A3[-=XPE)_3W1
M^8K>G:O\.!2:L$9T;^R-71]TP/,<V[3,@(_-(&2A95N!0YTM'/3)&&ENC&W+
M>235I:_1[-'C[1-DQE^%+6L.3)@<#"P_0D"9D[]#/%FP6$:<X-%:YNG%GM7^
MV9 ^S6:SN"@01]1P(J7MX>A]2[B=7UR2L]D\R9; SK92D0_9:#.2*Y*-_\="
MKH@@3O[C@@G;'QG?53#QAK&<%X7Z\SY.N:F94-?V0S:QX/_VQ ZHZ?NN,;:X
M2VD4VN8DW,*$@OET''(9QEA;):<"-?(VCV_68H9!?R[6!ZNEASO!>.RZP23B
M8\C";/AJ\I#YDTD8^LSD6X0[)Y>+&"R;Z:S[V(>IN?582=A/2+\CU+;_#8/]
M"$?ZO>KF*7S\F%]EMVEKI8C1((Q\[D2N[48.Y0%DSI'E3#PSBD)W&VFG*7D;
M\^OLH8HH H&/^2?(!V+1 ]#8#<<PS3"$%-ZV;0<4T/1<FXU#WXTL+_)VK(UT
MIQZGP!$8E,;TA[9^;R+]*0-V)O\7SU=25NI/;,_E-O4-PPY\Y@<T#,PP\ .3
M@46G6TBU;T&H_WS1^C=@9-;B.T5T#,X_Y:"I\9PFY.R.AXL2W##Y&$&TQXN'
MQK(_U&8O3 )E(*@-CXVVOTKU5W&@*5[^Z0^>94Y>%A!;)WP^S5).4I$A#0@(
M7++ ,)_0G%-08,:/%>OZUBL;,MT'SHKU.>PU/^A$W\#SUVID$Q9%IAF8%K==
MZGO4&ALA,ST_A""2;5.8 7NS:FY>]#O0]QG(VR<DT'J1R#6XPR"L'MN>[3J!
M[X1TXD4NG4Q,-W38%K X'B[F^_ZZ1^Q<[=U14/ZU*" S7#Y$4DZG//PB%J#H
M')SX/(^QAA!D=R3@279+8KDZ]0Z</O&&/Y,H3E!BX@+$I^0I$XU-I(AGBZ2D
M*<\61;(D!:2H1;04=ZH;L@! I54I B_D38%] ?/DA*;+ZEH$*6%VB_=A8!%C
M=E\<;TND[=+:O>2R]R>L)$QH4<A^I?> [Q4"]_ T5JXA=Q4H.F!IXW8) 24G
MG\_)Y7(&6OGG04'3 B*X/(ZZ!*-74?Z1QR5P'NLNBU15(PH]Q.21:SF!'091
M9%.3>PX$"AZWF.>/N>%OH;EK(6:094E 021*$$ST+W>6:Z*'656FK3R,["39
MCH;]'N?QK6\')XJ40!"=EF2NK1A?+$"6;<M1.K*R4HP+Q(?FA)R^NR!@'T<P
M\.L4A7YHSP.UYS*#L *8EU[_ H86K&VBKUP''H36CCGA$]<.J.<QRX:?)I%G
MA8YG>C]4IYZ[H2.9*4*NZXUITZ%I::K3ZJRH%<<V1G+D#]WYIG7G4\[1ZV"]
M4O1#8?B10Y+4"M8F$\.E8\,<^V-J1Z81>)8S#MV 43<R'&?R0X?JN8&>PU C
MZ+U^R+39T#H,7FRG47+L#YWZGG3JO"@6/._6+-<+&60[ 7/,L4VMT/-Y.)Y$
M+O@LR^#4?T+-6JD2_0=HVI@/[<-P.TU38[]^@>*A!2(M@I59(,\ACYQW-4H*
M<Z.R0D!\STG@[V1MTQQMZ!!9;>A7SR-6U;O_'-7H*]PF)?L_PZFTJ@^L%QHC
MW^U ?A8SEO!ON=!I>J-)%^3?--MR*@J&A7 Z>ZQ+?_OL&KLCOZ_QY9OD5=7(
M*C2,5\X#;.KM-(9?&L/[9"LNW69I^VZ:A_*Y/_F6?F=I6H$P0'J]V1PS&[?V
MV:9E8[$JF)B>&8:&[W'&G&V6;3&. O)>EEGX94#F-"<W-%EP\K_&R# <,L>M
M9M.G;,G\W9G"IV^\VB LRM;)^%J3E,AQ V_,/>HSQ_9=[-^U \>Q?,.UK<#?
M9C7@[.+#FR>3@M^?>7TV$:CL115ZKVR,<">>'SG4<B:&:8?<H6/;L!QW;(4A
M_'E0I1OM=-5'<04A[P=:,/J;M"GD%YI_X25Y__YTO\OH>\D%'K$&=9XRS(0X
M"98D%.M1,\ 4_!07?:PKBT5Q06A*((W"G:#7Y#K/;LLI)E1S7$"B!6$\BE.Y
M4T-6S\'XKF^R:O96B;U8,NNR@J&U84.6))>V*VLM'>FBC-BL^A"ZG/7@>$\K
M1W7;7\5=I_(F36S-B//(BZR)-?9MCNT<I@FB&P6<F@ZWMM@A_O *V7,M<YY'
M&X0&E\([)3!>6ZF<@GSQ!))3D*\T$ZGJHN!B% "JUD/QS)%8I*]RBS:22SPK
M6>+#;V-X-/(Q!9#A2LYOXH(S*5P@NC0-L9I-0W'^APBW2YHRFK-"+H>ROF1Y
M?$CK9%DO%XQV7]9?JR\1K<"$'/8GMOURA\W*CV#>'N$FNJ7\.M"K9VVYW7YM
M1[V^W7YM+_ZS;;>7VKM/OK1YT<>3,.$T%SGRM(9.DD8\4_U2GUT@.% 5;7^Z
M^/3N$[WF/^6<?L&6DYHWV@/F,& 8X(@AC4ID$TUNZ;+HF:8)330&2R@D+P5C
MNFI$5<S>,-'2>;CA.)3JDDX+Y$J+9O\I#1&.O4,)7<&27P>'QH#@?R_VE&R?
MEWQ&S)%A[K<T79F=_@AX52CV@LT9;EK$!I^,4%*M4Y.W&%?%HC/QS77.12%[
MM(<XLWO[>8=N=AID\2/X;P &-S^/G'G'H4*[6^V/N,-F97,W.43'BAUUUB-[
MY%9\FL"!\5#MS3J657\\Q Q&UD<2D;,H0D\/],<=[[7%%'\$5.;+%X.*]GU;
MK@? TFIS*-$VA#T/<BHZ[<&%",\D0GDABN_BO"A)0Y#GY4<WT"C!4HKQ'X"M
M@K%D42#GU'%@C08-"!.'?E'1!OQFGL<)L5PA<.;S(/@1W#U$H<DZK&V,!PIE
MB&4%^'0FX]] -O[5=!J09V,30(,I#P39]^#2B!Q +_"99?(,MNQ+LDS).2[7
M9:6N3)"&HR[=3K,D69+L%E/.8A$4,8MI7G<R*@$GAU\;_PITW7&(RD$WVFCL
M$I#1ML%X'\]B$,YO&<\*\#[$D)E*!GZ*LT)M=U.(?7UP)2C=P*HTC>@GQJQH
MDA3+3-5%('0K!A5VF)I>8Y(J6W)KT06FB]RW,D$#Y%XBU$'$A8G2#+G2'$)(
M0F/(7"D>!%@H?H-2J*<\BT52S_XD8>HFGDBR$3C(C.=9(98^U#EM(NM&.1!)
M,WZIL,SF>-S,(I5E'J":(*"D>YPS+.*+*S7%Y"C1$=V":81ZHWDFFA09.8Q?
M0'B2S\"8"J9,ZU,?*Z$=]EDG<J@5LD0G-HCR80P3AED:Q?FLMFQU@W\->HOS
M5;,UQG>%($*-2*WR<ZQ R,[M/@%JVA#N!QUB"1Q8X/H3HB\?"W"S6'8[T**B
M0_4XD*\:FNY'%XMP2FCC-($6+6*44UIJ;.J<&1B.196<X<&XL@RS'48 $@XZ
M!9,Q$$'4\ZA!!</]3BRN5OETTXP&@A++^:-0ZKR8QG/1Q)_C\4O/8K<1F3X4
MBD5^ ]:JJ#5(VSIP+\=>5@*&DG<8W[P@.9_!3:P1ABC/9HUUW1 HB#FJI[;)
M+R[E?)[04)]:2)::#FB.][(XA]!=Z1X:JC4#S9KYNR0>[#SP:2[C_V0YTM.E
MWCSJH>G3TY;HUN=;ZX2![$L)1)V$F2(D-K1(1?/L>IZP9U $^Q0P5\(I5 *#
MS[_@8OLKVS["7T5H?Z9D'?;=HZA>C;HG7 YX><MYVL6<0:M6+<V2>HKF;;0;
MFU!E)3;9,W54$-!.V$A?Y%-C_O@-<FN05*$+XT"$;"Z]:%1'*046E[!<-\0C
MXYGXN$BHN =B=0Q0Q QX?#1&-RPN.$4/O^)W8:KI D"0%V@:SR!,Z9>_702F
M34+2G'I]Q<-I"OA>+SLC<\E8*12ZGRX7>3K0HH[^G'102Q'5_?^J@=46:GID
M78<5ARMF#,1]DI*S&<]Q;09XW<><A@B2.4M<LF&+L)0\PKEB&1\)=M6LQI D
M;S@T(GH!2IH*:T!P^Z;R@8PC)X1A 4$#,X37&*<,?Y8/JT#,^36("Z"Z5+OQ
ML.WRMT6,%G.7P([?S?&>@>+7'!US63:NL\PT[*NX5\R]&I7I"H]TX@(,D9G\
M"_TD7%^);FM'N)50R'!P,8>00;K1!T41@][0N2],#I8-!6H$MP+X-ELDK IZ
M)- / [DQO!VTTS.<%N#B@5V8;A',=\7:FB#T9A*;=%I*6 /X+:Z[BO)G1X&I
MRILO(:D'LY@L=<NQ4H;J".(P+@ZXV(:'RZT+Z:II.V;CM8NK CLM8AMUK"3N
M/2A[?$U[0UUA+4] Z@CYOEY09"^X^20!W[@4P:C 7E8AFHV](KQI)Y^W<H[*
M1TB)6.'-AM"[8NR56%Y?#0KNSU6;?#PN=-NBI_/P7(F(DOZ.9+BI?JP5!CIC
M.DN'&Y6F4E_UT-7LMP?@")'%HV97DY6.Q0#!$+A'-B&(NDXDA)3@"A]R!_2L
MO,VDYP<6)Y&:.E[A&<@\%WD7&- $PHB2_*]I&.AC$C1$ A*=?AJ1XE*F/BI1
MJ<2L'@V>IT*]77@1_28S2*,V:7<+RAE=BOX+Y:2);+#0W'/M=05<!0=\&S*O
M2I#RR)H^!(L2T9F!^T076H@S7^4[-IK0H",J$ 6HZM%%?6AL_>@*_W[;5Z'[
MIN8;VK-.Y$5<S44KB4YCC;C+'9 6 B/M+F#.,N +/F1*;[CJ@E&O%("'X<$D
ML7(H$@K]. FY[;_J8VGN2T&TBH+F2VUUA/&(BV!TB0O#\0P<F#JP,$="AF"%
MY)2T%'C3/,9P#.TS3+Q(1/24B<@)I"A5G3!"#(5/DR6_\FGSY<>;YL]=_JK%
M]+95!D/<&%:P.7^L3(P6 D=<[*\1ZBS4JMM*5LSH4NK[U'FU@(I<PG7%^@49
MC+!%WL@$+M^A61,G:'>9QHTV$=5M+%%MR?S6J';A6*&_7U3G&2:1<;?1E5:Z
MT!K$%!%V)$BG9125YQ5!$>YS+M$&-<671.E>+:X7B<#Y@6<#) 8J4QB@$A;B
M0")50Z],8H5INPXNAK1%-4",,7@(LT(-J(&A19&%,:U%C:=@A,+J4=(V]#P(
MB[G8[]EE+=!(X%_AK)0%0+KV\W,]-KG/7&YG47[T,>VQC^GYNT*4#*(CVIS@
M=IDOD8Z.#<* #2HW([?J!!#PM###:B@[:/H]A;W9,8:LXH2 Z\M0N"JU9I1=
M"99V\,Z]T:98C5H/,JN9P HEN%8)MF"MTEVE4& ^4WX-J,NZ%:C8=8;MLE0L
MS62RHT 5V46=5<\:*@KT)@_D7*JL?+.$9F)7DNHM>-?AB^O2  ):98[-"J/N
M:59=2X<G:4VON90YN(>\<D>\9@(6E.M0.GH@4K(@-1<0I3+3T/B_5H*0P6Z"
MS<\R7(-T$=>0Q<7:]S9'.8D)=#*TFGE6:2)&:XBW:-0J#*D<5*LV*0FHSH[B
M<I&V#F5C\6C<[]7#6[$TW%(T 4V;32BLX+?PO#Y(#6>4<1TH%?>KHZKJ#<NK
MGKH=U&OW5Z6ZIK RD.=AB=2T.]^JT&_+3O<:9\/T8HJ^N"HT]:C$5FMB<J8
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M]F<P-U"^.@HRMCS!#]-REL"'_P=02P,$%     @ P(!V5?6;^7YJ)@  ?/P
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M7_*EZ.U,RU>BE%_*[2")1^E+D<@A?$)/?BE^V:&?5QO\?H"'VLJG8"3/J\E
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MXX$.4;/$32CM:R$+LVQ+*77+5M0 U%N^U-UX#3GJJ_# B+HI:!S51#DM[*<
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MDK.15,!3+5(402*++;QK'_\YZ(@#U(L.NGOX#WQVB)_AM@Z[O1UXI3+Q.-_
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MY3:/H.)$;-*D<B'J=Z''K9I,=(LI2ID.E*L",4Y.I@EEQ##8UAH)=N>0P)/
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M!WL[*U)::<(($MB5K9?[,=13G-:X.ABY,!%7/A>A'ITFYA6X8>9E.7P=[?X
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M9BSS.N0]7!7</8!Y[P%1]2WBZ(@O);=,:!Q(Y;0&5'WWJ+Z,1V-.>695F$V
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M5XXLOLJ/[O=[I6;OG\*IT8<>SZY_BKUB7O,T<[$18IJCBNSJ+U!+ P04
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M%:)F:Q.EIHS9-4%%!.6A'CPH:=LK4FMQ95H!L0#6Z-,^LU+'"C]@K)B4$FM
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MG07M(_UN$BT\Y,Y?C7SUR?:27W%V1[;/WSC5=T!M%FA @?O 7]H^9FADTHZ
MWPG4=M[>YGBO W6(]2*@(<"5MY>RU^FO,VBEX;<'%?,K5I0H^X>LG.T#']"F
MN@$$KKVOK'T<8.31/H#</91[UH1C9%'>%M)/A-1"\-3U4&_1LSY2*PBY(RB?
MCLVNEHS:O[UQA=5R-,/PU&PIH471YFBM*N2>W0U.UEQX,8IGM[),0U576"U)
M,PQ/U9826E1MCM:J0NZYW7(D'[>_><AG+#,DM<;48A@Q>&+ZR+<H:0S53\I
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M.Z.MQ/W\8<FF7?+27MI1V%C"<W% _NQ\&Y%_Y,^T/_X/4$L! A0#%     @
MP(!V54GH(>FW'   N:(  !,              ( !     &)R:&,Q,# T-#4X
M-U\X:RYH=&U02P$"% ,4    " # @'95]9OY?FHF  !\_   %P
M    @ 'H'   8G)H8S$P,#0T-3@W7V5X,3 M,2YH=&U02P$"% ,4    " #
M@'95F*._]T8#   Z#P  $0              @ &'0P  97)N82TR,#(R,3$R
M,BYX<V102P$"% ,4    " # @'95K;'8F7\(  !U6   %0
M@ '\1@  97)N82TR,#(R,3$R,E]L86(N>&UL4$L! A0#%     @ P(!V55;D
M46;;!0  \CX  !4              ( !KD\  &5R;F$M,C R,C$Q,C)?<')E
:+GAM;%!+!08     !0 % $L!  "\50     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
